Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST trial of niraparib versus placebo in ctDNA-positive HER2-negative or triple-negative early breast cancer
NL-OMON59228Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and triple-negative breast cancer (TNBC) comparing Niraparib with Placebo (2 arms). Started Aug 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON59228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59228.